医薬品リファレンス
Lazertinib
Lazertinib is a medicine in the class oncology. It is used for non-small cell lung cancer.
- 薬効分類: Oncology
- 効能・効果: non-small cell lung cancer
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01EB09
- 一般的な剤形
- 錠剤
- 既知の相互作用
- 1 (中等度: 1)
- 商品名
- 2
- 国・市場
- 2
何に使われるか
作用のしくみ
Kinase inhibitor of EGFR that inhibits EGFR exon 19 deletions and exon 21 L858R substitution mutations at lower concentrations than wild-type EGFR.
成人の通常用量（添付文書の要約）
First-line EGFR-mutated NSCLC (exon 19 deletion or exon 21 L858R), with amivantamab: 240 mg orally once daily with or without food; continue until disease progression or unacceptable toxicity; give any time prior to amivantamab on the same day.
妊娠と授乳
- 妊娠
- Unsafe Can cause fetal harm: no human data; in animals it reduced embryo-fetal survival and fetal weight (rats) and caused malformations (rabbits) at about 4 and 0.5 times human exposure. Verify pregnancy status and use effective contraception during and for 3 weeks after treatment.
- 授乳
- Unsafe No data on milk levels or infant effects. Because of possible serious adverse reactions in the infant, do not breastfeed during treatment and for 3 weeks after the last dose; follow the amivantamab label for the combination.
報告されている副作用
- Rash
- Nail toxicity
- Musculoskeletal pain
- Edema
- Stomatitis
- Venous thromboembolism
禁忌
- None.
注意が必要な方
- Serious and fatal VTE (36% in MARIPOSA); give prophylactic anticoagulation for the first four months; vitamin K antagonists are not recommended.
- ILD/pneumonitis can occur; monitor for symptoms, withhold if suspected, discontinue if confirmed.
- Severe dermatologic reactions including rash; prophylactic measures recommended; limit sun exposure.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (1)
- Amivantamab + Lazertinib Moderate
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Lazertinibの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Lazertinib used for?
Lazertinib is a medicine in the class oncology. It is used for Non-small cell lung cancer.
What side effects have been reported with Lazertinib?
Rash, Nail toxicity, Musculoskeletal pain, Edema, Stomatitis, Venous thromboembolism.
Can Lazertinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: no human data; in animals it reduced embryo-fetal survival and fetal weight (rats) and caused malformations (rabbits) at about 4 and 0.5 times human exposure. Verify pregnancy status and use effective contraception during and for 3 weeks after treatment. Breastfeeding: Unsafe. No data on milk levels or infant effects. Because of possible serious adverse reactions in the infant, do not breastfeed during treatment and for 3 weeks after the last dose; follow the amivantamab label for the combination.
What does Lazertinib interact with?
MediHelp lists 1 known interactions for Lazertinib. Moderate: 1. The most serious include Amivantamab.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
